Functional activity of bone marrow progenitor cells in patients with chronic myeloid leukemia related to individual response to therapy
AbstractThe paper presents an effective method of the monitoring of individual response of the patients with chronic myeloid leukemia (CML) to the therapy with tyrosine kinase inhibitors (TKi). The growth patterns analysis of hematopoietic cells from CML patients showed that functional activity of bone marrow progenitor cells of the patients with complete response to TKi therapy was significantly lower (p < 0.05) in comparison with the colony-forming efficiency of bone marrow sampled from patients with a resistance to the therapy. The correlations were revealed between numbers of colony-forming units and the percentage of Ph+ cells in the bone marrow. This correlation was positive for the group of patients who were alternatively treated with the hydroxyurea and negative for the group of individuals with the resistance to TKi therapy.
Дягиль И. С. Субоптимальный ответ при лечении иматинибом ХМЛ как критерий риска развития резистентности // Укр. журнал гематології та трансфузіології. – 2009. – № 4 (9). – С. 27–29.
Hughes T. Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapy / T. Hughes, A. Hochhaus // Semin Hematol. – 2009. – Vol. 46. – P. 111–115. doi: 10.1053/j.seminhematol.2009.01.008
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity / A. S. Corbin, A. Agarwal, M. Loriaux et al. // J. of Clin. Inv. – 2011. – Vol. 121. – N 1. – P. 396–409. doi: 10.1172/JCI35721
Leber B. CML biology for the clinician in 2011: Six impossible things to believe before breakfast on the way to cure // Curr. Oncol. – 2011. – Vol. 18, N 4. – P. 185–190.
Philadelphia chromosome (Ph1)-negative chronic myelogenous leukemia (CML): A clonal disease with origin in a multipotent stem cell / P. J. Fialkow, R. J. Jacobson, J. W. Singer et al. // Blood. – 1980. – Vol. 56, N 1. – P. 70–73.
Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance / W. W. Zhang, J. E. Cortes, H. Yao et al. // J. Clin. Oncol. – 2009. – Vol. 27, N 22. – P. 3642–3649. doi: 10.1200/JCO.2008.19.4076
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons «Attribution» 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.